By PPN News Staff
The FDA approved a new indication for ceftolozane-tazobactam (Zerbaxa, Merck) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older.
Ceftolozane-tazobactam was first approved by the agency in 2014 to treat complicated intraabdominal infections and complicated urinary tract infections.
“Pneumonia in ventilated patients remains a significant clinical challenge and is associated with